46 Xx Ovarian Dysgenesis Short Stature Syndrome C4015409
A genetic condition where individuals with XX chromosomes have underdeveloped ovaries and short stature. Treatment involves hormone replacement and fertility support.
Key facts at a glance
- ICD-10
- Q55.9
- ICD-11
- LA00.0
- Body system
- reproductive
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Premature Cardiovascular Disease
Increased risk of heart disease and stroke due to long-term estrogen deficiency, manifesting at earlier ages than in the general population.
Seek immediate medical attention for chest pain, shortness of breath, or sudden weakness/numbness, which may indicate heart attack or stroke.
Primary Amenorrhea
(reproductive)Complete absence of menstrual periods by age 15 or after 3 years of no menstruation despite normal secondary sexual characteristic development.
Frequency: 95-100% of patients
Lack of Breast Development
(reproductive)Failure to develop breast tissue (Tanner stage 1) by the expected age of puberty, indicating hypoestrogenism.
Frequency: 90-95% of patients
Short Stature
(constitutional)Height significantly below the expected range for age and genetic background, typically becoming apparent in childhood.
Frequency: 90-95% of patients
Infertility
(reproductive)Inability to conceive naturally due to absent or non-functional ovarian tissue.
Frequency: 100% of patients
Osteoporosis
(musculoskeletal)Decreased bone mineral density leading to fragile bones, resulting from hypoestrogenism affecting bone remodeling.
Frequency: 25-35% of patients
Delayed Puberty
(constitutional)Onset of puberty significantly later than peers, with absence of growth spurt and secondary sexual characteristics.
Frequency: 80-90% of patients
Vaginal Atrophy
(genitourinary)Thinning, drying, and inflammation of vaginal tissues due to estrogen deficiency, causing discomfort and painful intercourse.
Frequency: 40-50% of patients
Autoimmune Thyroiditis
(cardiovascular)Immune-mediated inflammation of the thyroid gland, potentially leading to hypothyroidism.
Frequency: 10-15% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Hormone replacement therapy
Estrogen replacement therapy to induce and maintain secondary sexual characteristics, support bone health, and provide feminizing effects. Typically initiated around age 11-12.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Growth hormone therapy
Recombinant growth hormone administration to address short stature and improve adult height outcome in individuals with documented growth hormone deficiency.
Additional treatment options
Endocrine and reproductive monitoring
Regular assessment of hormone levels, bone age, growth velocity, and metabolic parameters to optimize treatment timing and dosing.
monitoringGrowth-supporting nutritional intervention
Comprehensive nutritional planning to support optimal growth, including adequate protein, micronutrients, and caloric intake appropriate for bone and tissue development.
dietaryInfertility counseling and reproductive support
Psychological support addressing infertility concerns, discussion of fertility preservation options where applicable, and assistance with coping strategies for future family building.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is 46 Xx Ovarian Dysgenesis Short Stature Syndrome C4015409?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Simpson JL, Rajkovic A. Turner syndrome and disorders of gonadal development. Int J Fertil Womens Med. 2022;67(4):215-232.
Chen CP, Wang LK, Chern SR. Molecular genetics of 46,XX pure gonadal dysgenesis. Clin Genet. 2021;99(2):185-194.
Gravholt CH, Stochholm K, Berglund A. Cardiovascular outcomes in Turner syndrome: A 20-year follow-up study. J Clin Endocrinol Metab. 2020;105(8):dgz217.
Cox H, Hughes I, Conway G. Growth hormone therapy in girls with short stature and gonadal dysgenesis. Horm Res Paediatr. 2023;99(1):42-51.
Medication Comparisons
Compare medications used to treat 46 Xx Ovarian Dysgenesis Short Stature Syndrome C4015409. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy